Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail
-

Background for Today's Discussion

Steven D. Vaughn, DVM

Director
Office of New Animal Drug Evaluation

Center for Veterinary Medicine
U.S. Food & Drug Administration
Rockville, MD 20855 

 Background for Today's VMAC Discussion - slide 1

Slide 2

Guidance for Industry #152

  • Evaluating the safety of Antimicrobial New Animal Drugs with
    Regard to Their Microbiological Effects on Bacteria of Human
    Health Conern
  • October 23, 2003

 

 Background for Today's Discussion - slide 2

Slide 3

Qualitative Risk Assessment

  • Release assessment
    - H, M, L
  • Exposure assessment
    - H, M, L
  • Consequence assessment
    - Critical important, Highly important, Important
  Background for Today's Discussion - slide 3

Slide 4

Assessment outcomes Integrated into a RISK ESTIMATION

  • HIGH
  • MEDIUM
  • LOW
 Background for Today's Discussion - slide 4
Slide 5      
Approval Conditions Category 1
(High) 		 Category 2
(Medium) 		 Category 3
(Low) 
Marketing Status  Rx  Rx/VFD  Rx/VFD/OTC 
Extra-Label Use (ELU)  ELU restrictions  Restricted in some
cases 		 ELU permitted 
Extent of use  Low  Low, medium  Low, medium, high 
Post-approval Monitoring  Yes  Yes  In certain cases 
Advisory Committee Review  Yes  In certain cases  No 
 		 Background to Today's Discussion - slide 5
-
-
-
-